149 related articles for article (PubMed ID: 37879774)
1. Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
Qiu Z; Huang H; Zhang Y; Chen D
J Thorac Oncol; 2023 Nov; 18(11):e138-e139. PubMed ID: 37879774
[No Abstract] [Full Text] [Related]
2. Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.
Nisman B; Oleinikov K; Nechushtan H; Maimon O; Atlan K; Peled N; Gross D; Peretz T; Meirovitz A; Grozinsky-Glasberg S
J Thorac Oncol; 2023 Mar; 18(3):369-376. PubMed ID: 36503175
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
[TBL] [Abstract][Full Text] [Related]
4. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumors (NETs) - experience of a single Center.
Şincu MC; Cocuz IG; Tinca AC; Niculescu R; Sabău AH; Chiorean DM; Morariu SH; Cotoi OS
Rom J Morphol Embryol; 2021; 62(2):457-463. PubMed ID: 35024733
[TBL] [Abstract][Full Text] [Related]
6. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine characteristics in malignant lung tumors: implications for diagnosis, treatment, and prognosis.
Senderovitz T; Skov BG; Hirsch FR
Cancer Treat Res; 1995; 72():143-54. PubMed ID: 7702985
[No Abstract] [Full Text] [Related]
8. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
9. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
11. Approach to the diagnosis of neuroendocrine lung neoplasms: variabilities and pitfalls.
Hammar SP
Semin Thorac Cardiovasc Surg; 2006; 18(3):183-90. PubMed ID: 17185177
[TBL] [Abstract][Full Text] [Related]
12. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
13. Bronchopulmonary carcinoid tumors--a significant diagnostic problem.
Kedra P; Jeleń M; Szkudlarek-Gruszczyńska T; Leśkow E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():146-61. PubMed ID: 9337533
[TBL] [Abstract][Full Text] [Related]
14. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
15. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
17. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
18. [Chromogranin A: a marker of neuroendocrine tumors].
D'Herbomez M; Gouze V
Ann Biol Clin (Paris); 2002; 60(6):641-6. PubMed ID: 12446227
[TBL] [Abstract][Full Text] [Related]
19. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
[TBL] [Abstract][Full Text] [Related]
20. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
